OBIO® and IPON Renew Multi-Year Collaboration to Advance Ontario’s Sovereign IP Capacity OBIO® and Intellectual Property Ontario (IPON) have renewed their memorandum of understanding (MOU) to ensure that Ontario’s next generation of companies developing innovative human health products continue to access optimal…
IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic…
Next Health in Peoria Hosting Grand Opening, Bringing Advanced Longevity & Preventive Health Services to Arizona Next Health, the world’s most advanced and comprehensive brand of health optimization and longevity centers, invites the community and media to its newest location in…
Trinseo Takes Proactive Step to Strengthen Financial Foundation and to Drive Long-Term Sustainable Growth Trinseo PLC a specialty material solutions provider, announced that it entered into a Restructuring Support Agreement with parties that hold a majority of its debt. This…
GC Biopharma Presents New Data at CIS 2026 to Expand Analytical Understanding of IVIG Product Characteristics GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of new data at the 2026 Clinical Immunology Society (CIS) Annual Meeting…
Butterfly Network Appoints Caroll H. Neubauer to Board of Directors Butterfly Network, Inc. a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of Caroll H. Neubauer to its Board of Directors, effective…
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults Bristol Myers Squibb announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active…
Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB Two River, LLC and Vida Ventures both part of the Bellco Health ecosystem, acknowledged the announced acquisition of Candid…
Chemical Reduction Solutions LLC Expands Partnership with Simoniz USA Inc. to Exclusively Commercialize Nanobubble Technology in the Car Wash Industry Chemical Reduction Solutions LLC (“CRS”), a developer of hydrodynamic cavitation-based nanobubble technology, today announced an expanded partnership with Simoniz USA…
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals, Inc. announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine,…
Availity’s Inaugural Abrasion Index Reveals Where Payer-Provider Friction Hits Healthcare Hardest Availity®, the nation’s largest health information network, today released its first annual Availity Abrasion Index, a research-informed report that measures where administrative friction between health plans and providers is highest…
Sunnybrook Announces $41-Million Gift to Advance Canada’s Global Leadership in Clinical Trials Sunnybrook Health Sciences Centre is proud to announce a $41M philanthropic investment in Sunnybrook Clinical Trials. The investment expands dedicated infrastructure, capacity and expertise across Sunnybrook to optimize how clinical…